Shares jump as CryoLife's anti-rejection pulmonary heart valve reaches the US
This article was originally published in Clinica
Executive Summary
The first "decellularised" heart valve - a valve made from donated tissue from which the cells have been removed - has been approved for sale in the US market. The share price of the graft's manufacturer, CryoLife, jumped more than 20% on the news - the largest percentage gain that day - rising by $1.38 to reach $8.13.